Brace Pharma
VC Fund
Rockville, United States
Brace Pharma is a VC fund in Rockville focused on Biotechnology and Health Care. Brace Pharma Capital is a strategic investment company formed by EMS S/A, the largest pharmaceutical company in Brazil, and high net worth biotech investors. We invest in innovative, life changing therapies for diseases with a high degree of unmet medical need and insufficient treatment options.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Brace Pharma invests in
Stages Brace Pharma invests in
Countries Brace Pharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Vinzenz Ploerer
|
|||
Investment Focus
Industry
- Biotechnology 15 (65%)
- Health Care 9 (39%)
- Therapeutics 9 (39%)
- Medical 7 (30%)
- Genetics 4 (17%)
Stage
- Series B 9 (39%)
- Series C 5 (22%)
- Series D 3 (13%)
- Series A 2 (9%)
- Private Equity 1 (4%)
Country
- United States 12 (52%)
- United Kingdom 2 (9%)
- Canada 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Vinzenz Ploerer
Founder, President & CEO
|
Founder, President & CEO | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Antiva Biosciences
|
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco. | $31M / Series D / Nov 02, 2021 | |
Turnstone Biologics
|
Turnstone Biologics is a privately-held clinical-stage biotech company. Turnstone Biologics’ mission is to deliver breakthrough cancer immunotherapies by advancing two leading and complementary platforms targeting tumor immunity, to improve survival for people with cancer. | $80M / Series D / Jul 14, 2021 | |
Contineum Therapeutics
|
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to thenervous system. | $80M / Series C / Feb 11, 2021 | |
ReViral
|
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates,enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds. | $44M / Series C / Aug 25, 2020 | |
F2G
|
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $60.8M / Private Equity / Aug 12, 2020 | |
HotSpot Therapeutics
|
HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $65M / Series B / May 21, 2020 | |
|
Contineum Therapeutics
|
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to thenervous system. | $32M / Series B / Dec 18, 2019 | |
Avidity Biosciences
|
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $100M / Series C / Nov 13, 2019 | |
|
Avidity Biosciences
|
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $16M / Series B / Oct 17, 2018 | |
|
ReViral
|
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates,enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds. | $55M / Series B / Aug 01, 2018 | |
| See all 23 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Brace Pharma invest in?
Brace Pharma invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brace Pharma?
Public channels for Brace Pharma include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Brace Pharma?
The team at Brace Pharma includes Vinzenz Ploerer (Founder, President & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
